Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Science News
Fluorescent-Protein Spin Qubit: Reading What a Genetically Encoded Quantum Sensor Could Mean for Cell Biology
Paper: A fluorescent-protein spin qubit (Nature, 4 Sep 2025) What you will learn In a nutshellWhat’s novel?How it works (OADF/ODMR)Key resultsWhy it matters In a nutshell Enhanced yellow fluorescent protein (EYFP) is realized as an optic... -
Science News
News Watch | Hypoxia & Kidney: A tRNA-derived small RNA protects kidneys via “RNA autophagy”
Lead: Kidneys are prone to hypoxia, fueling AKI-to-CKD progression. A 2025 Science study shows that a hypoxia-induced “tRNA-Asp-GTC-3′tDR” safeguards kidney cells by maintaining autophagic flux through RNA autophagy. This adds a new laye... -
Science News
Cancer and Accelerated Aging: Molecular and Cellular Insights from Recent Studies
In recent years, cancer and aging have increasingly been understood not as separate biological phenomena, but as interconnected processes. Immune decline and chronic inflammation in cancer patients may not be caused solely by treatment s... -
Oncology FDA Approval
News Watch: in vivo CAR-T RACE (2025 Global Update)
Last updated: 2025-09-01 JST What you will learn Three-Line SummaryWhy in vivo (now)?Company Highlights (Q3 2025)Two Paths, One GoalClinical KPIs to Watch Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. B... -
Science News
News Watch: EV × Neurons × Tumor Immunity—Tumor-derived sEVs reprogram nociceptors to drive immunosuppression (with a look at IL-6/IL-6R blockade and potential label expansion) Vol.2
Appendix: IL-6R Inhibitors & Company Landscape (as of Aug 2025) A quick map of who owns which IL-6R blockers and current approved uses, to inform combo trials and partnering around the neuro-immune loop discussed above. What you will... -
Oncology Drug
Transcription Factors and DNA Repair Collision: Mutagenesis and Neoantigen Formation as a New Strategy for Cancer Immunotherapy
Introduction: A New Relationship Between Transcription Factors and DNA Repair Recent cancer research has highlighted DNA replication errors and defects in repair mechanisms as central drivers of tumorigenesis. The mismatch repair (MMR) s... -
Science News
News Watch: EV × Neurons × Tumor Immunity—Tumor-derived sEVs reprogram nociceptors to drive immunosuppression (with a look at IL-6/IL-6R blockade and potential label expansion) Vol.1
Fresh data in Science Signaling (2025) show that tumor-derived small extracellular vesicles (sEVs) reprogram TRPV1+ nociceptors, boosting IL-6 and Substance P, thereby increasing MDSC infiltration and CD8 T-cell exhaustion—a neuro-immune... -
Oncology Drug
Pancreatic Cancer’s “Two Shots on Goal”: Reading 3 Strategic Bets That Could Break the Survival Plateau
Introduction: Why Pancreatic Cancer Is So Difficult to Treat Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a dismal 5-year survival rate of about 10%. Three major challenges underlie this poor ... -
Oncology Drug
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Comprehensive Summary and Future Outlook
Trilogy Subtitles+Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio... -
Oncology Drug
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance③
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Oncology Drug
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance②
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Oncology Drug
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance①
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Beginner-friendly
Summer Beginner Series Grand Summary Part 2|The Rise of Bispecific Antibodies and the Future of Next-Generation Modalities
This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs... -
AI Drug Discovery
Can RNA Become a Drug Target? ― Insights from Science and Biotech Frontlines
In recent years, the question of whether RNA can serve as a viable therapeutic target has become one of the most exciting debates in life sciences and drug discovery. In recent years, the question of whether RNA can serve as a viable the... -
Science News
Latest Science News: Cancer, Obesity, and Aging — New Insights into Immune Recovery through Weight Loss
Recent research highlights that aging and obesity each independently promote cancer progression and can act synergistically to worsen outcomes. Recent research highlights that aging and obesity each independently promote cancer progressi... -
Oncology FDA Approval
Viking’s VK2735 Plunge: What 50% Stock Drop Reveals About the Novo–Lilly Duopoly Era
On August 19, 2025, U.S.-based biotech company Viking Therapeutics announced results from its Phase 2 trial of the oral obesity drug VK2735. While the therapy demonstrated up to 12.2% weight loss over 13 weeks, a high discontinuation rat... -
Beginner-friendly
Summer Beginner Series Grand Summary Part 1|Anti-Obesity Drugs, ADCs, and In vivo CAR-T — From Beginner to Intermediate Insights
This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modaliti... -
Beginner-friendly
Summer Special Beginner Series Summary|In vivo CAR-T: Evolution and Future of Cellular Immunotherapy
This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, This article is the comprehensive summary of our Morningglorysciences Summer Beginner ... -
Beginner-friendly
Summer Special Beginner Series Summary|Antibody-Drug Conjugates (ADC): Evolution and Future Horizons
This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Drug Conjugates (ADCs). This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on Antibody-Dru... -
Beginner-friendly
Summer Special Beginner Series Summary|Anti-Obesity Drugs: From GLP-1 to Next-Generation Therapies
This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. This article is a comprehensive summary of our Morningglorysciences Summer Beginner Series on anti-obesity drugs. Throughou...